Corrigendum to “Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy” [Heliyon 4 (12) (December 2018) e01039]

• Xiaosheng Wu,
• Yanli Li,
• Xin Liu,
• Chunhua Chen,
• Susan M. Harrington,
• Siyu Cao,
• Tiancheng Xie,
• Tu Pham,
• Aaron S. Mansfield,
• Yiyi Yan,
• Eugene D. Kwon,
• Liewei Wang,
• Kun Ling,
• Haidong Dong

Affiliations

Xiaosheng Wu

Department of Medicine Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA

Yanli Li

Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA

Xin Liu

Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA

Chunhua Chen

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA

Susan M. Harrington

Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA

Siyu Cao

Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA

Tiancheng Xie

Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA

Tu Pham

Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA

Aaron S. Mansfield

Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA

Yiyi Yan

Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA

Eugene D. Kwon

Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA

Liewei Wang

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA

Kun Ling

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA

Haidong Dong

Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA; Corresponding author.